Dr. Ashkan Bahrani, MD

Dr. Bahrani practices at University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System.

Dr. Bahrani's NPI, 1144214727, was assigned on September 9, 2005. Dr. Bahrani holds Maryland license D54841.

Dr. Bahrani's primary practice is University of Maryland Medical Center, at 22 South Greene Street, Baltimore, MD 21201 in Baltimore City. The practice phone is (410) 328-8667.

Dr. Bahrani's primary practice is University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System. Dr. Bahrani is also affiliated with University of Maryland Upper Chesapeake Medical Center Bel Air. The medical group on file is UM Upper Chesapeake Hematology & Oncology - Bel Air. Dmand AI also links Dr. Bahrani to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bahrani practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Bahrani's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Bahrani is licensed in Maryland.

CMS data shows 34,932 Medicare services from Dr. Bahrani across 21 procedure codes in 2024, for 536 Medicare patients. Medicare paid $1,574,980 for them.

CMS counts 536 Medicare patients who saw Dr. Bahrani in 2024. The largest group is 75 to 84, with 230 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bahrani's median patient age at 73, with 51% women.

In 2024, Dr. Bahrani wrote 464 Medicare Part D claims for 124 patients. 84% of them were for generic drugs. CMS names the drug for 314 of them, across 8 drugs with 11 or more claims each, at $15,774 in total drug cost. In 2023, CMS named 307 claims across 8 drugs.

Dr. Bahrani accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bahrani as offering telehealth.

Dmand AI links Dr. Bahrani to 10 clinical trials, 7 of them phase 3 studies. 9 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Breast Carcinoma In Situ. National Cancer Institute (NCI) sponsors the most, 8.

CMS Open Payments shows 15 general payments to Dr. Bahrani from 7 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Bristol-Myers Squibb Company paid the most, $95.